SCHEMBL22279799

SCHEMBL22279799

NN(C1CCNCC1)[C@@H]1CC1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 11/20 0.47
MAOB P27338 11/20 0.47
SLC6A2 P23975 2/20 0.47
CISD1 Q9NZ45 1/20 0.47
HTR1B P28222 1/20 0.47
HTR2A P28223 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC18A3 Q16572 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
MAOA P21397 9/20 0.44
CYP2C19 P33261 4/20 0.41
CYP2B6 P20813 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28255285 0.78 KDM1A (0.43) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL23856027 0.78 KDM1A (0.43) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL18817699 0.78 KDM1A (0.43) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL28932470 0.74 KDM1A (0.45) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL1945840 0.73 SLC18A3 (0.67) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL1944988 0.73 SLC18A3 (0.67) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL1944998 0.73 SLC18A3 (0.67) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL1944661 0.73 SLC18A3 (0.67) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL12965591 0.73 KDM1A (0.51) KDM1AMAOBSLC6A2CISD1HTR1B
SCHEMBL19609379 0.73 KDM1A (0.51) KDM1AMAOBSLC6A2CISD1HTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020152280-A1 LSD1 INHIBITORS FOR USE IN THE TREATMENT OF TYPE 2 DIABETES FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD (ES) 2020-07-30 WO disclosed